Showing results (2161-2170 of 2,282) with videos related to

Sort By:
Pageof 229
Journal of Global Oncology|May 17, 2019
Overall Survival of Patients With ALK-Positive Metastatic Non-Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort StudyIlya Tsimafeyeu, Fedor Moiseenko, Sergei Orlov, et al.
The Lancet. Oncology|February 7, 2020
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b studyLecia V Sequist, Ji-Youn Han, Myung-Ju Ahn, et al.
Molecular Phylogenetics and Evolution|March 17, 2020
A combined approach of mitochondrial DNA and anchored nuclear phylogenomics sheds light on unrecognized diversity, phylogeny, and historical biogeography of the torrent frogs, genus Amolops (Anura: Ranidae)Yun-He Wu, Fang Yan, Bryan L Stuart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 26, 2023
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsLecia V Sequist, James Chih-Hsin Yang, Nobuyuki Yamamoto, et al.
Molecular Syndromology|March 2, 2026
Different Diagnoses, Common Ancestry: 22q11.2 Deletion Syndrome and Wiskott-Aldrich Syndrome in the Same FamilyAnastasia Bobreshova, Irina Efimova, Anna Mukhina, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 7, 2020
Structural basis of nanobody recognition of grapevine fanleaf virus and of virus resistance lossIgor Orlov, Caroline Hemmer, Léa Ackerer, et al.
Oncotarget|May 3, 2018
Novel water-soluble lignin derivative BP-Cx-1: identification of components and screening of potential targets in silico and in vitroElena I Fedoros, Alexey A Orlov, Alexander Zherebker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III TrialKaren Kelly, Nasser K Altorki, Wilfried E E Eberhardt, et al.
World Journal of Stem Cells|June 17, 2021
Disease modifying treatment of spinal cord injury with directly reprogrammed neural precursor cells in non-human primatesVladimir P Baklaushev, Oleg V Durov, Vladimir A Kalsin, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 3, 2017
Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung CancerMartin Reck, Normand Blais, Erzsebet Juhasz, et al.
Pageof 229